Abstract 525P
Background
Glioblastoma (GBM) is characterized by an “immune-deserted” tumor microenvironment (TME) consisting of tumor-associated macrophages (TAMs) and tumor infiltrating lymphocytes (TILs). We aimed to investigate the prognostic role of tumor tissue markers correlating with overall survival (OS) and progression-free survival (PFS).
Methods
By immunohistochemistry (IHC), we analyzed on 31 archival formalin-fixed paraffin embedded (FFPE) tissue specimens: CD3, CD4, CD8, CD20, CD45, CD68, CD163, CD66b and PDL-1. Expression values were classified according to density score from 0 to 4 (0=no expression; 1=1-25%; 2=26-50%, 3=51-74%; 4=75%-100%) in two areas: Vascular/perivascular (V) and diffuse in tumor parenchyma (D). Percentage of infiltrating immune system cell was calculated by the rate of absolute number of positive stained cells/total number of cells multiplied by 100.
Results
All tissues were negative for PDL1 and only two positive for CD20. We observed that CD68+ macrophage and CD66b+ neutrophils expressed in V showed a statistically significant prognostic role (p-value of 0.027 and 0.029 respectively) (Table). CD68-V showed a prognostic role for PFS (p-value 0.032), while CD66b-V expression did not. CD3, CD4, CD8, CD45 and CD163 were not associated with OS and PFS.
Table: 525P
Characteristics | Univariable models OS | Multivarible model OS | Univariable models PFS | Multivarible model PFS | ||||
HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | |
CD68V | ||||||||
0-1 | 1.00 | - | 1.00 | - | 1.00 | - | 1.00 | - |
2-4 | 0.42 (0.19-0.91) | 0.027 | 0.46 (0.21-0.99) | 0.049 | 0.41 (0.18-0.92) | 0.032 | 0.45 (0.20-1.01) | 0.054 |
CD66bV | ||||||||
0-1 | 1.00 | - | 1.00 | - | 1.00 | - | 1.00 | - |
2-4 | 0.38 (0.16-0.90) | 0.029 | 0.41 (0.17-0.98) | 0.046 | 0.45 (0.17-1.12) | 0.087 | 0.49 (0.19-1.24) | 0.136 |
Conclusions
Despite having a smaller cohort of tissues, we showed a different expression of immune markers. In particular, CD68-V was associated with a significant positive impact on both OS and PFS. This relation could be partially explained because TAM do not raise only from peripheral blood, but also from resident microglia. Moreover, we observed high density of CD66b+ cells in V related to OS probably for growth factors overproducted by tumor cells with their recruitment from blood. Further studies are needed in large series to explore the prognostic role of selected TME immune molecules to develop therapeutic strategies that aim to hit different components of GBM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRST and Area Vasta Romagna Ethics Committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10
538P - Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Presenter: Giulia Pretelli
Session: Poster session 10